10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Streptococcus pneumoniae Senses a Human-like Sialic Acid Profile via the Response Regulator CiaR.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Streptococcus pneumoniae is a human-adapted pathogen that encounters terminally sialylated glycoconjugates and free sialic acid (Sia) in the airways. Upon scavenging by the bacterial sialidase NanA, Sias serve as carbon sources for the bacteria. Unlike most animals in which cytidine-monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) converts Sia N-acetylneuraminic acid (Neu5Ac) into N-glycolylneuraminic acid (Neu5Gc), humans have an inactive CMAH, causing an absence of Neu5Gc and excess Neu5Ac. We find that pneumococcal challenge in Cmah(-/-) mice leads to heightened bacterial loads, virulence, and NanA expression. In vitro, NanA is upregulated in response to Neu5Ac compared with Neu5Gc, a process controlled by the two-component response regulator CiaR and requiring Sia uptake by the transporter SatABC. Additionally, compared with Neu5Gc, Neu5Ac increases pneumococcal resistance to antimicrobial reactive oxygen species in a CiaR-dependent manner. Thus, S. pneumoniae senses and responds to Neu5Ac, leading to CiaR activation and increased virulence and potentially explaining the greater susceptibility in humans.

          Related collections

          Author and article information

          Journal
          Cell Host Microbe
          Cell host & microbe
          Elsevier BV
          1934-6069
          1931-3128
          Sep 14 2016
          : 20
          : 3
          Affiliations
          [1 ] Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
          [2 ] Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.
          [3 ] Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences; Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA 92093, USA.
          [4 ] Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Cellular and Molecular Medicine; Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA 92093, USA.
          [5 ] Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, 171 76 Stockholm, Sweden. Electronic address: birgitta.henriques@ki.se.
          Article
          S1931-3128(16)30318-3 NIHMS807949
          10.1016/j.chom.2016.07.019
          5025396
          27593514
          723cde5f-30fe-4f4c-804a-6ba5625b518a
          History

          Comments

          Comment on this article